Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
about
Centrosome - a promising anti-cancer targetMolecular modeling and docking of small molecule inhibitors against NEK2NIMA-related kinase 2 regulates hepatocellular carcinoma cell growth and proliferationAbnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosisA centrosome clustering protein, KIFC1, predicts aggressive disease course in serous ovarian adenocarcinomasE2F activators signal and maintain centrosome amplification in breast cancer cells.Differential expression of centrosome regulators in Her2+ breast cancer cells versus non-tumorigenic MCF10A cells.An integrated overview of spatiotemporal organization and regulation in mitosis in terms of the proteins in the functional supercomplexes.Role of NEK2A in human cancer and its therapeutic potentials.Autoinhibition and relief mechanism for Polo-like kinase 4.Recent Advances and New Strategies in Targeting Plk1 for Anticancer TherapySilencing of E2F3 suppresses tumor growth of Her2+ breast cancer cells by restricting mitosisFOXM1 is a therapeutic target for high-risk multiple myeloma.Targeting NEK2 as a promising therapeutic approach for cancer treatment.Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy.NEK2 serves as a prognostic biomarker for hepatocellular carcinoma.Centrosome amplification: a suspect in breast cancer and racial disparities.Effect of silencing NEK2 on biological behaviors of HepG2 in human hepatoma cells and MAPK signal pathway.Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma.The E2F activators control multiple mitotic regulators and maintain genomic integrity through Sgo1 and BubR1.PLK4: a link between centriole biogenesis and cancer.STIL balancing primary microcephaly and cancer.Low expression of NEK2 is associated with hepatocellular carcinoma progression and poor prognosis.PLK4 is essential for meiotic resumption in mouse oocytes.NEK2 promotes hepatocellular carcinoma migration and invasion through modulation of the epithelial-mesenchymal transition.Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway.Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma.Centrosome aberrations and chromosome instability contribute to tumorigenesis and intra-tumor heterogeneityYLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect
P2860
Q28077520-482F12C1-1BDF-4414-9D59-58817F9DE3D1Q28468337-AB124ECC-1BEE-454F-A9DD-A15E3FB7EF54Q33598631-5381A31C-DAC3-4947-A8E8-31D403174B28Q33802966-6D88A8B2-12CB-4110-8963-0FEB5C340970Q33816666-A667F0BE-A803-40D5-8D42-785C603F5AE1Q33899840-A8BB67E1-401C-4A8C-8FFC-0CBC9AE46FB0Q34273997-5683B51E-9525-4AE2-ACDD-0097127CFB76Q34419568-E6AA3F25-A515-458D-BB03-4A2C60D703B2Q35090475-ED48B2A7-0D56-459D-AEC8-F600B2F9BCCEQ35128950-469FB907-2490-4D3B-A866-FF38E9BF67D2Q36386336-147846B7-F8CB-4E41-946F-0564FD6D9A9FQ36545731-76651D62-4F65-4E50-9BC2-F5B370105F36Q36783627-F8CEE2EE-A181-4197-BD37-5C6BAA7FD43FQ36956969-418C27E7-B263-4BEF-8CF7-DCA3B32D5918Q37015737-F49E152D-42F3-45C8-90B1-5F123AB0F60EQ37588101-48AD9C2A-7505-4BB2-85DD-9B1B552B663EQ38780267-114E48BA-1595-4AB7-AD22-2E52EA9DE2CFQ38838219-39132BB7-C5A0-410A-BFC9-0D18337609DAQ45865884-3D053007-CA20-479C-9527-1F7B0C8B96F6Q47109520-044A1A63-D725-4685-9747-6505715C3859Q47368506-D568C68E-951B-4DA5-8D79-2D1B97D46FD1Q47851151-C3CDED76-1516-42D3-A6AA-B7B422E2BED4Q48008338-7DF5C57C-50A1-429E-A844-CF4620C966EBQ48584046-0BB8BAB4-0FB1-4CB5-8D2A-B93368C63FDBQ49331594-C6BF92F8-212F-4C10-BD6C-8E6C0D032A15Q49911300-0FDC9A3F-A0F0-4BA8-8C8D-C34D62372236Q50059082-39DAD05C-13C9-4B60-B726-D6CF38C6CA36Q58132668-2DD575BF-1146-4D9C-8A2F-FB0AD4B13E6EQ58594110-FD3BE975-B84B-4170-BFFA-3F828A551B80
P2860
Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
@en
Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
@nl
type
label
Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
@en
Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
@nl
prefLabel
Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
@en
Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
@nl
P2860
P356
P1476
Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
@en
P2093
Harold I Saavedra
Mihaela Marina
P2860
P304
P356
10.2741/4212
P577
2014-01-01T00:00:00Z